Health care technology company Zelis Holdings L.P. (Zelis) plans to use proceeds from a new seven-year, $2.1 billion, first-lien term loan and cash on hand to fund a distribution to its shareholders. The transaction will weaken its credit metrics with pro forma financial leverage of 7.2x and EBITDA coverage of 2.1x, versus 3.5x and 4.9x previously, for the 12 months ended second-quarter 2024. We lowered our long-term issuer credit rating on Zelis and issue ratings on its existing debt to 'B' from 'B+'. We also assigned our 'B' issue rating to the company's new first-lien, $2.1 billion term loan due 2031. The stable outlook reflects our expectation that Zelis will sustain its strong operating performance and maintain its highly leveraged